Tumor Antigen Targeting
Tumor Antigen Targeting - Related Videos
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
0 Views •
Cited by 17 •
2019
This protocol describes a detailed workflow for the generation and ex vivo characterization of oncolytic viruses for expression of immunomodulators, using measles viruses encoding bispecific T cell engagers as an example. Application and adaptation to other vector platforms and transgenes will accelerate the development of novel immunovirotherapeutics for clinical translation.
04:42
An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells
0 Views •
2025
This video demonstrates a technique for the ex vivo generation of tumor antigen-specific chimeric antigen receptor (CAR) T cells. Retroviral vectors carrying transgenic RNA are mixed with spleen cells in a medium supplemented with interleukin-2 to promote T-cell survival and proliferation. The mixture is then transferred to a plate coated with recombinant human fibronectin fragments and centrifuged to facilitate the fusion of the virus with the cell, allowing the RNA to integrate into the host...
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
0 Views •
Cited by 1 •
2020
Here we present a protocol to study the in vivo localization of antibodies in mice tumor xenograft models.
03:36
Pretargeted Radioimmunotherapy: A Method for Targeted Delivery of Therapeutic Radionuclides to Tumors
0 Views •
2023
This video describes the technique of pretargeted radioimmunotherapy or PRIT, in which immunoconjugates followed by radioligands are administered for treating tumors. This radioimmunotherapy reduces radiation doses to healthy tissues and utilizes radionuclides with very low half-lives incompatible with antibody-based vectors.
03:12
An Avidin-Biotin Conjugation Technique for Presenting Target Antigens on Mycobacterium bovis BCG
0 Views •
2025
The video demonstrates a technique for loading antigens on Mycobacterium bovis BCG to improve its immunogenic properties. The method uses the avidin-biotin system to coat the bacterial surface with exogenous antigens.
FAQs
The central distinction is whether an antigen is tumor-specific or tumor-associated. Tumor-specific molecules provide a more selective target, whereas tumor-associated molecules may also occur in healthy tissue, increasing the importance of controlling unintended immune effects. This distinction influences how researchers judge therapeutic selectivity and the potential for damage to normal tissues.
Antigen expression and tumor heterogeneity strongly influence whether targeting reaches all malignant cells. If expression varies among cells or across a tumor, an immune response or therapeutic agent may act unevenly, allowing some cancer cells to remain less visible to the chosen strategy. Researchers therefore consider expression patterns when evaluating expected effectiveness.
Recognition mechanism determines the type of response that follows. Antibodies can direct treatment toward an antigen, T-cell receptors can support antigen recognition by T cells, and engineered immune cells can be designed for targeted activity. These routes may lead to immune-cell activation, direct killing, or cytotoxic delivery, so they are not interchangeable.
Design begins by matching the selected antigen with an appropriate targeting approach, while considering expression, tumor heterogeneity, immune access, and effects on normal tissues. The strategy may use antibodies, T-cell receptors, or engineered immune cells, depending on the intended response. These considerations help frame experiments around selectivity, access, and anticancer activity.
In immunology and infection research, tumor antigen targeting provides a framework for developing cancer vaccines, monoclonal antibodies, and adoptive cell therapies. These applications use different therapeutic formats but share the goal of focusing immune activity or treatment on cancer-related molecules. Comparing them helps researchers study how antigen recognition can be translated into cancer treatment.
Useful evaluation focuses on both antitumor activity and selectivity. Researchers can examine whether targeting activates immune cells, produces direct killing, or delivers cytotoxic treatment, while also considering immune access and effects on normal tissues. Antigen heterogeneity remains an important interpretive limitation because a strong response against one antigen-bearing population may not represent the whole tumor.